• Bluelight Census 2018

    Global Drug Survey has partnered with Bluelight to create a sample of people who reported using Bluelight in the last 7 days.
    This report is based on the data from 1480 people who used Bluelight in the last 7 days and completed GDS up to and including questions about novel substance use.
    The survey was live in November-December 2017.

    Summary of results:
    • Most Bluelighters (70% ) come from English-speaking countries (US, UK, Australia, Canada)
    • Bluelightersare typically young 'white' males (median age 20, 84% male, 88% 'White')
    • Over half of Bluelighters are currently studying (56% )
    • A quarter (24% ) have completed a university qualification
    • Half (51% ) report being in paid employment, including 28% that work full-time
    • 20% report their occupation as 'professional'
    • Almost half (45% ) report 'never' going clubbing
    • Lifetime drug use rates include 94% cannabis, 71% LSD and 68% MDMA
    • Lifetime use of prescription benzodiapines (64% ) and opioids (60% ) is significant
    • Lifetime rates of novel drug use are high, e.g. LSD analogues (21% ), novel benzos (21% )
    • Clearnet forums (such as Bluelight) are used extensively for harm reduction information
    • Almost all Bluelighterswho reported trying MDMA for the first time in the last 12 months used Bluelight to research MDMA beforehand

    Limitations: the sample may not be representative of the Bluelight population and the results rely on accuracy of self-report.

    Read/download the full report here: bluelightcensus2018.pdf

    Thanks to all of the community members who took the time to complete this survey.
    Thanks also to Global Drug Survey for partnering with Bluelight in 2018.